Abstract
Finding the means to ameliorate and prevent bone destruction as well as control inflammation is an urgent issue in the treatment of rheumatoid arthritis (RA). Recently, it has been demonstrated that osteoclastogenesis plays an important role in the bone destruction and pathogenesis of RA. Here, we review the effects of disease modifying anti-rheumatic drugs (DMRAD) on the amelioration of bone destruction and osteoclastogenesis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
